Psychedelics Company Silo Wellness Announces USD$495,000 Strategic Equity Investment by Socially Conscious Metaverse and Psychedelics Holding Company Orthogonal Thinker

Psychedelics Company Silo Wellness Announces USD$495,000 Strategic Equity Investment by Socially Conscious Metaverse and Psychedelics Holding Company Orthogonal Thinker

Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K70) ("Silo Wellness" or the "Company"), a leading global psychedelics company, is pleased to announce that it has entered into a subscription agreement (the "Subscription Agreement") with respect to a strategic investment (the "Transaction") with Orthogonal Thinker, Inc. ("Orthogonal Thinker") an arm's length third-party investor, pursuant to which the Company will issue 12,555,180 units of the Company (the "Units") for aggregate gross proceeds to the Company of US$495,000. Each Unit will consist of one common share of the Company ("Common Share") and one Common Share purchase warrant (each, a "Warrant") exercisable for one Common Share at a price per Common Share of C$0.05 for a period of two years after the date of issue. Within 180 days of closing of the Transaction ("Closing"), Orthogonal Thinker will purchase additional Units (or convertible debt) for aggregate gross proceeds of US$505,000 based on the prevailing market price of the Common Shares.

At Closing, it is anticipated that David Nikzad and Jason Hobson of Orthogonal Thinker will join the board of directors of the Company (the "Board"). Additionally, Mr. Nikzad will be appointed Co-Chief Executive Officer and Mr. Hobson will be appointed Chief Operating Officer of the Company.

Douglas K. Gordon, Chief Executive Officer of Silo Wellness, said, "We are very excited to ally Silo Wellness with Orthogonal Thinker. David Nikzad and his team at Orthogonal Thinker have done amazing things and we welcome their strategic advice and industry-leading vision."

David Nikzad, cofounder and Chief Executive Officer of Orthogonal Thinker, said, "We chose to invest in Silo Wellness because of its firm commitment to helping people in need with psychedelics through retreats in Jamaica and the Bob Marley brand partnership. We look forward to advising Silo Wellness on how to best grow Marley One and psychedelic retreats."

Summary of Investor Rights Agreement

Concurrent with the closing of the Transaction, the Company and Orthogonal Thinker will enter into an investor rights agreement (the "Investor Rights Agreement"), pursuant to which Orthogonal Thinker shall be entitled to designate two nominees (each, an "Investor Nominee") for election to the Board and shall be entitled to appoint the Chief Executive Officer of the Company and the Chief Operating Officer of the Company. The Investor Rights Agreement will also provide that Orthogonal Thinker will receive an additional two Investor Nominees for election at the next shareholder meeting of the Company (the "AGM").

For so long as Orthogonal Thinker owns at least 10% of the issued and outstanding Common Shares (on a fully-diluted basis), Orthogonal Thinker will be entitled to certain participation and top-up rights further set out in the Investor Rights Agreement. In addition, the Investor Rights Agreement provides Orthogonal Thinker with certain registration rights with respect to its Common Shares.

Closing Conditions

The Transaction is subject to customary closing conditions and applicable regulatory approvals, including receipt of certain voting support agreements from certain shareholders of the Company with respect to the AGM.

ABOUT Silo Wellness

Silo Wellness is a growth-oriented holding company focused on functional mushroom and psychedelic opportunities that benefit from a unified ecosystem and exceptional leadership. Founded in 2018 and headquartered in Toronto, Silo Wellness has operations in Jamaica and Oregon. Silo Wellness is a publicly-traded company on the Canadian (CSE: SILO) and Frankfurt (FSE: CK70) exchanges and trading on the OTCQB Venture Market (OTCQB: SILFF).

Silo Wellness offers a diverse and growing portfolio of functional mushroom products, psychedelic wellness retreats in Jamaica and Oregon, cultivation of psychedelic mushrooms and truffles in Jamaica, development of a brick-and-mortar smart shop in Jamaica, and intellectual property, focused initially on the commercialization of its metered-dosing psilocybin nasal spray.

In March 2021, Silo Wellness announced a multi-year licensing agreement with the family of legendary musician Bob Marley for the exclusive worldwide rights to brand, market and sell a distinct product line of functional and psychedelic mushrooms. The Marley One line of functional mushrooms is available at www.MarleyOne.com.

For more information about Silo Wellness, please visit www.silowellness.com.

For further information, please contact:

Silo Wellness Media Relations:
hello@trailblaze.co

Silo Wellness Investor Relations:
(778) 383-6740
ir@silowellness.com

ABOUT ORTHOGONAL THINKER

Orthogonal Thinker is a holding company focused on health and well-being through clean-label, whole plant products, including psychoactive compounds. Orthogonal Thinker utilizes deep learning technology and emotional intelligence (EI) to elevate and empower humanity with plant medicine to set a new standard for health and mental wellness: a "New Standard of Farma."

Contact Data

Investor Contact:
David Nikzad
david@orthogonalthinker.com

Media Contact:
Samantha Mullett
sam@serotonin.io
(858) 705-2529

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION: This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates, and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to the closing of the Transaction, the appointment of Mr. Nikzad and Mr. Hobson to the Board and as officers of the Company and the Company's future business plans. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, regulatory, political and social uncertainties and the potential impact of COVID-19. Such risks and uncertainties include, among others, the risk factors included in Silo Wellness's continuous disclosure documents available on www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Readers should not place undue reliance on the forward-looking statements and information contained in this news release. Silo Wellness assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/112678

News Provided by Newsfile via QuoteMedia

SILO:CNX
Born Defense

Born Defense Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
Born Defense

Born Defense

Psychedelic Healing Right Now & Pharmaceutical Biotech

Psychedelic Healing Right Now & Pharmaceutical Biotech Keep Reading...
Numinus Wellness Inc. Announces Fourth Quarter Fiscal 2025 Results and Provides Corporate Update

Numinus Wellness Inc. Announces Fourth Quarter Fiscal 2025 Results and Provides Corporate Update

Q4 Fiscal 2025 Highlights Revenue of $2.3 million, a 29.0% increase over Q3 2025 Gross profit of $1.4 million, compared to a gross profit of $0.8 million in Q3 2025 Cash position of $0.5 million as of August 31, 2025 Subsequent to Quarter End On April 18, 2026, President Donald Trump signed an... Keep Reading...
The Calmer Co. Secures Exclusive Global Distribution Agreement for Kava Extract Ingredients up to $25 million

The Calmer Co. Secures Exclusive Global Distribution Agreement for Kava Extract Ingredients up to $25 million

Brisbane, Australia - The Calmer Co. International Limited (ASX: CCO), a leading consumer packaged goods company specialising in kava and other natural products that promote relaxation and sleep support, is pleased to announce the execution of an Exclusive Distribution Agreement with a... Keep Reading...
Gloved hand holds a cluster of brown mushrooms growing from a gray substrate block.

Psychedelics Market Trends: H1 2026 Review and Forecast

The psychedelic medicine market is moving swiftly from speculative research mode toward an institutional, prescription-oriented framework as federal policy in the US becomes more supportive.President Donald Trump’s April 18 executive order on ibogaine and other psychedelic therapies helped... Keep Reading...
A pill bottle with US flag and coloured pills.

Medical Cannabis and Psychedelics Reforms Reshaping Mental Health Markets

The landscape for medical cannabis and psychedelic therapies has rapidly shifted in just a few weeks following recent executive actions in the US. Between the formal rescheduling of medical cannabis to Schedule III and an executive order aimed at accelerating mental health treatments, several... Keep Reading...
Dried mushrooms surrounded by translucent capsules on a white background.

Executive Order Sparks New Phase for Psychedelic Biotech, but Risks Remain

On April 18, US President Donald Trump was joined by top health officials in the Oval Office to sign Accelerating Medical Treatments for Serious Mental Illness, an executive order (EO) to expand research into ibogaine. This signals the strongest federal endorsement yet of psychedelic medicine as... Keep Reading...
Numinus Wellness Responds to Trump Executive Order on Psychedelic Therapies

Numinus Wellness Responds to Trump Executive Order on Psychedelic Therapies

Company's clinical research operations and therapist training programs directly positioned to support accelerated research and commercialization timelinesNuminus Wellness Inc. (OTC: NUMIF) today acknowledged the Executive Order signed by President Donald J. Trump directing United States federal... Keep Reading...
Born Defense

Born Defense Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Interactive Chart

Latest Press Releases

Related News